Search clinical trials for: STI571

Total 94 results

M.D. Anderson Cancer Center

Terminated

Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma

Uterine Cancer

United States
Novartis Pharmaceuticals

Completed

A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

Leukemia

China
Novartis Pharmaceuticals

Completed

A Study of Nilotinib Versus Imatinib in GIST Patients (ENESTg1)

Gastrointestinal Stromal Tumor (GIST)

China, South Africa, United States, France, Italy, United Kingdom, Germany, Taiwan, Turkey, Canada, Egypt, Singapore, Argentina, Austria, Poland, Russian Federation, Spain, Sweden, Thailand, Korea, Republic of, Bulgaria, Denmark, Japan and more
Novartis

Completed

Effect of Food on Bioavailability of Modified Release Formulations of Imatinib

Healthy
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Minimal Residual Disease | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
Children's Oncology Group
National Cancer Institute (NCI); EsPhALL Network/ BFM Study Group

Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | T Acute Lymphoblastic Leukemia | Mixed Phenotype Acute Leukemia

United States, Canada, Puerto Rico, Australia, Finland, New Zealand, Saudi Arabia, Germany, Austria, Belgium, Chile, Czechia, France, Italy, Netherlands, Sweden, Switzerland, Hong Kong, Israel
Novartis Pharmaceuticals

Completed

Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic Sclerosis

Systemic Sclerosis, Scleroderma

United States, Germany, Italy, Switzerland, United Kingdom
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group; American...

Completed

Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor

United States
University of Washington
National Cancer Institute (NCI)

Withdrawn

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Recurrent Adult Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Recurrent B Lymphoblastic Lymphoma | Refractory B Lymphoblastic Lymphoma | B Lymphoblastic Lymphoma | Recurrent T Lymphoblastic Leukemia/Lymphoma | Refractory T Lymphoblastic Lymphoma | T Acute Lymphoblastic Leukemia | T...

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST) (INV555)

Gastrointestinal Stromal Tumors

Saudi Arabia, Taiwan, Turkey, Egypt, Thailand, Russian Federation, South Africa, Lebanon, India, Tunisia, Algeria, Jordan
M.D. Anderson Cancer Center

Completed

Late Chronic Phase Chronic Myelogenous Leukemia

Leukemia

United States
M.D. Anderson Cancer Center
Novartis

Completed

Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma

Mesothelioma

United States
M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Completed

Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia

Leukemia

United States
M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Completed

Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer

Prostate Cancer

United States
M.D. Anderson Cancer Center
Novartis

Completed

Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer

Head and Neck Cancer | Squamous Cell Cancer

United States
Novartis Pharmaceuticals

Completed

Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)

Gastrointestinal Stromal Tumors
M.D. Anderson Cancer Center
Novartis

Completed

Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States
University of Bologna
Novartis

Completed

Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia

Chronic Myeloid Leukemia
Astex Pharmaceuticals, Inc.
Eisai Inc.

Completed

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Chronic Myelogenous Leukemia

United States, Canada
M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Terminated

Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C

Myelogenous Leukemia, Chronic, Chronic Phase

United States
Novartis Pharmaceuticals

Completed

Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Chronic Myeloid Leukemia (CML)

Korea, Republic of
Novartis Pharmaceuticals

Completed

Effect of Food on Bioavailability of a Modified Release Formulation of Imatinib

Healthy
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Chronic Myelogenous Leukemia

Canada, Italy, United States, United Kingdom, Belgium, Germany, France, Switzerland, Austria, Denmark, Spain, Norway, Sweden, Netherlands, New Zealand, Australia
M.D. Anderson Cancer Center

Completed

Gleevec Study for Patients With Ovarian Cancer

Ovarian Cancer

United States
M.D. Anderson Cancer Center
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia

Leukemia, Myeloid, Chronic

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients

Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

Chronic Myeloid Leukemia, BCR-ABL1 Positive

United States, Canada
Novartis Pharmaceuticals

Active, not recruiting

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

United States, China, Hungary, Japan, Belgium, Germany, Canada, Singapore, Australia, Israel, Netherlands, Spain, Italy, Korea, Republic of, Bulgaria, France, United Kingdom, Czechia, Sweden, India, Malaysia, Denmark, Taiwan, Norway, Fi... and more
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Hematologic Diseases | Chronic Myelogenous Leukemia | CML | Leukemia, Myeloid Chronic

Taiwan, Italy, Spain, United Kingdom, Germany, United States, Korea, Republic of, France, Russian Federation, Canada, Denmark, Poland, Portugal, Austria, Czechia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Minimal Residual Disease | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission

United States
University of Washington
National Cancer Institute (NCI)

Completed

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

Recurrent Disease | Adult Acute Lymphoblastic Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Adult B Acute Lymphoblastic... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Estrogen Receptor Positive | Progesterone Receptor Positive | Postmenopausal | KIT Positive | PDGFR Positive

United States
Joanne Jeter
National Cancer Institute (NCI); Merck Ltd.

Withdrawn

Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification

Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIIA Skin Melanoma
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor (S0502)

Gastrointestinal Stromal Tumor

United States, Canada
Novartis Pharmaceuticals

Completed

Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

Chronic Myelomonocytic Leukemia | Hypereosinophilic Syndrome | Systemic Mastocytosis | Dermatofibrosarcoma

Australia
Hospital Virgen de la Salud

Completed

Imatinib in KIT-negative Systemic Mastocytosis

Systemic Mastocytosis

Spain
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases

Prostate Cancer | Metastatic Cancer

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

Leukemia

United States
Novartis Pharmaceuticals

Completed

Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)

Gastrointestinal Stromal Tumors

Japan
M.D. Anderson Cancer Center

Completed

Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients

Leukemia

United States
M.D. Anderson Cancer Center

Completed

Autologous Transplantation for Chronic Myelogenous Leukemia

Chronic Myelogenous Leukemia

United States
University of Bologna
Novartis

Unknown

Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias

Myeloproliferative Disorders | Hypereosinophilic Syndrome | Chronic Eosinophilic Leukemia (CEL)

Italy
Novartis Pharmaceuticals

Recruiting

Asciminib Roll-over Study

Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Chronic Myelogenous Leukemia

Denmark, Spain, France, Germany, Lebanon, Italy, Argentina, Czechia, Portugal, United Kingdom, Brazil, Mexico, Russian Federation, Taiwan, Austria, Canada, Korea, Republic of, Turkey, United States, Singapore, Japan, Bulgaria, Poland, Romani... and more
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Ipilimumab and Imatinib Mesylate in Advanced Cancer

Metastatic Melanoma | Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Melanoma | C-KIT Tyrosine Kinase Protein Overexpression | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Gastrointestinal Stromal Tumor | Pathologic Stage IV Cutaneous Melanoma... and other conditions

United States
Novartis Pharmaceuticals

Active, not recruiting

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

GIST and CML

China, Turkey, Singapore, France, Switzerland, Thailand, United States, Romania, Hong Kong, Finland, United Kingdom
Novartis Pharmaceuticals

Completed

An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

United States, Germany, United Kingdom, Italy, France, Switzerland
Novartis Pharmaceuticals

Completed

Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumors

United States, France, Belgium, Germany
Novartis Pharmaceuticals

Completed

A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients

3rd Line GIST

France, United Kingdom, Belgium, Canada, Spain, Netherlands, Japan, United States
Novartis Pharmaceuticals

Completed

A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) (ENESTnd)

Myelogenous Leukemia, Chronic

South Africa, Italy, Belgium, Japan, Taiwan, Turkey, Canada, Germany, Spain, Egypt, United States, Singapore, Austria, France, Netherlands, Sweden, United Kingdom, Korea, Republic of, Hong Kong, Thailand, Russian Federation, Brazil, Hungar... and more

Search clinical trials for: STI571

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations